Literature DB >> 8475072

Inhibition of rate of tumor growth by creatine and cyclocreatine.

E E Miller1, A E Evans, M Cohn.   

Abstract

Growth rate inhibition of subcutaneously implanted tumors results from feeding rats and athymic nude mice diets containing 1% cyclocreatine or 1%, 2%, 5%, or 10% creatine. The tumors studied included rat mammary tumors (Ac33tc in Lewis female rats and 13762A in Fischer 344 female rats), rat sarcoma MCI in Lewis male rats, and tumors resulting from the injection of two human neuroblastoma cell lines, IMR-5 and CHP-134, in athymic nude mice. Inhibition was observed regardless of the time experimental diets were administered, either at the time of tumor implantation or after the appearance of palpable tumors. For mammary tumor Ac33tc, the growth inhibition during 24 days after the implantation was approximately 50% for both 1% cyclocreatine and 1% creatine, and inhibition increased as creatine was increased from 2% to 10% of the diet. For the other rat mammary tumor (13762A), there was approximately 35% inhibition by both 1% cyclocreatine and 2% creatine. In the case of the MCI sarcoma, the inhibitory effect appeared more pronounced at earlier periods of growth, ranging from 26% to 41% for 1% cyclocreatine and from 30% to 53% for 1% creatine; there was no significant difference in growth rate between the tumors in the rats fed 1% and 5% creatine. The growth rate of tumors in athymic nude mice, produced by implantation of the human neuroblastoma IMR-5 cell line, appeared somewhat more effectively inhibited by 1% cyclocreatine than by 1% creatine, and 5% creatine feeding was most effective. For the CHP-134 cell line, 33% inhibition was observed for the 1% cyclocreatine diet and 71% for the 5% creatine diet. In several experiments, a delay in appearance of tumors was observed in animals on the experimental diets. In occasional experiments, neither additive inhibited tumor growth rate for the rat tumors or the athymic mouse tumors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8475072      PMCID: PMC46288          DOI: 10.1073/pnas.90.8.3304

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Creatine biosynthesis during embryonic development. False feedback suppression of liver amidinotransferase by N-acetimidoylsarcosine and 1-carboxymethyl-2-iminoimidazolidine (cyclocreatine).

Authors:  J B Walker; J K Hannan
Journal:  Biochemistry       Date:  1976-06-15       Impact factor: 3.162

2.  Chemotherapy of Morris hepatoma 3924A: correlation of size and weight of tumor and preliminary data with 5-fluoro-2'-deoxyuridine (5-FUDR; NSC-27640).

Authors:  K W Lo; E E Miller; H P Morris; K C Tsou
Journal:  Cancer Chemother Rep       Date:  1973 Sep-Oct

3.  Synthesis and properties of N-acetimidoyl derivatives of glycine and sarcosine.

Authors:  T Wang
Journal:  J Org Chem       Date:  1974-11-29       Impact factor: 4.354

4.  Activation of muscle glycolysis: a role for creatine phosphate in phosphofructokinase regulation.

Authors:  K B Storey; P W Hochachka
Journal:  FEBS Lett       Date:  1974-09-15       Impact factor: 4.124

5.  Enzymes of energy metabolism from a vertebrate facultative anaerobe, Pseudemys scripta. Turtle heart phosphofructokinase.

Authors:  K B Storey; P W Hochachka
Journal:  J Biol Chem       Date:  1974-03-10       Impact factor: 5.157

6.  Muscle creatine: in vivo depletion by feeding beta-guanidinopropionic acid.

Authors:  R P Shields; C K Whitehair
Journal:  Can J Biochem       Date:  1973-07

7.  Inhibition of muscle pyruvate kinase by creatine phosphate.

Authors:  R G Kemp
Journal:  J Biol Chem       Date:  1973-06-10       Impact factor: 5.157

8.  Specificity of creatine kinase for guanidino substrates. Kinetic and proton nuclear magnetic relaxation rate studies.

Authors:  A C McLaughlin; M Cohn; G L Kenyon
Journal:  J Biol Chem       Date:  1972-07-10       Impact factor: 5.157

9.  Cyclocreatine phosphate as a substitute for creatine phosphate in vertebrate tissues. Energistic considerations.

Authors:  T M Annesley; J B Walker
Journal:  Biochem Biophys Res Commun       Date:  1977-01-10       Impact factor: 3.575

10.  Accumulation of analgo of phosphocreatine in muscle of chicks fed 1-carboxymethyl-2-iminoimidazolidine (cyclocreatine).

Authors:  G R Griffiths; J B Walker
Journal:  J Biol Chem       Date:  1976-04-10       Impact factor: 5.157

View more
  23 in total

1.  Inhibition of cytosolic and mitochondrial creatine kinase by siRNA in HaCaT- and HeLaS3-cells affects cell viability and mitochondrial morphology.

Authors:  Holger Lenz; Melanie Schmidt; Vivienne Welge; Thomas Kueper; Uwe Schlattner; Theo Wallimann; Hans-Peter Elsässer; Klaus-Peter Wittern; Horst Wenck; Franz Staeb; Thomas Blatt
Journal:  Mol Cell Biochem       Date:  2007-07-28       Impact factor: 3.396

Review 2.  Creatine metabolism: energy homeostasis, immunity and cancer biology.

Authors:  Lawrence Kazak; Paul Cohen
Journal:  Nat Rev Endocrinol       Date:  2020-06-03       Impact factor: 43.330

Review 3.  Oral creatine supplementation and skeletal muscle metabolism in physical exercise.

Authors:  José L M Mesa; Jonatan R Ruiz; M Marcela González-Gross; Angel Gutiérrez Sáinz; Manuel J Castillo Garzón
Journal:  Sports Med       Date:  2002       Impact factor: 11.136

Review 4.  The role of phosphometabolites in cell proliferation, energy metabolism, and tumor therapy.

Authors:  S Mazurek; C B Boschek; E Eigenbrodt
Journal:  J Bioenerg Biomembr       Date:  1997-08       Impact factor: 2.945

Review 5.  Creatine kinase in non-muscle tissues and cells.

Authors:  T Wallimann; W Hemmer
Journal:  Mol Cell Biochem       Date:  1994 Apr-May       Impact factor: 3.396

6.  Cyclocreatine in cancer chemotherapy.

Authors:  B A Teicher; K Menon; D Northey; J Liu; D W Kufe; R Kaddurah-Daouk
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Kinetics of creatine uptake in the perfused mouse liver: a 31P-n.m.r. study of transgenic mice expressing creatine kinase (CKBB) in the liver.

Authors:  S Masson; B Quistorff
Journal:  Biochem J       Date:  1994-10-15       Impact factor: 3.857

8.  Creatine protects against excitoxicity in an in vitro model of neurodegeneration.

Authors:  Just Genius; Johanna Geiger; Andreas Bender; Hans-Jürgen Möller; Thomas Klopstock; Dan Rujescu
Journal:  PLoS One       Date:  2012-02-08       Impact factor: 3.240

Review 9.  Creatine in T Cell Antitumor Immunity and Cancer Immunotherapy.

Authors:  Bo Li; Lili Yang
Journal:  Nutrients       Date:  2021-05-13       Impact factor: 5.717

10.  Phosphocreatine interacts with phospholipids, affects membrane properties and exerts membrane-protective effects.

Authors:  Malgorzata Tokarska-Schlattner; Raquel F Epand; Flurina Meiler; Giorgia Zandomeneghi; Dietbert Neumann; Hans R Widmer; Beat H Meier; Richard M Epand; Valdur Saks; Theo Wallimann; Uwe Schlattner
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.